Celltrion expects its annual operating profit to surpass 1 trillion won for the first time in 2025, driven by strong global sales of high-value biosimilars. For the fourth quarter, it projects sales of 1.28 trillion won and operating profit of 472.2 billion won, marking year-on-year increases of 20.7% and 140.4%, respectively. The growth stems from an expanding portfolio of new products and enhanced production capacity.
Celltrion announced its fourth-quarter earnings guidance on December 31, projecting sales of 1.28 trillion won and operating profit of 472.2 billion won. These figures represent year-on-year increases of 20.7% in sales and 140.4% in operating profit, achieving the company's highest-ever quarterly results. The operating margin is expected to reach 36.8%.
For the full year, sales are forecasted at 4.11 trillion won, up 15.7% from the previous year, with operating profit at 1.16 trillion won, a 136.9% rise. This marks the first time annual sales exceed 4 trillion won and operating profit surpasses 1 trillion won, fueled by robust global sales of biosimilars.
New products including Remsima SC, Yuflyma, Vegzelma, and Steqeyma are anticipated to post double-digit growth in the fourth quarter, comprising over 60% of total sales. "Increased global sales of its flagship biosimilars buoyed full-year earnings," the company stated in a press release.
To support ongoing growth, Celltrion is bolstering production capacity. It plans to finalize the acquisition of Eli Lilly's biopharmaceutical plant in Branchburg, New Jersey, for 460 billion won by year-end and commence full-scale contract manufacturing next year to supply U.S. markets. The firm has expanded its approved products from six to 11, targeting 18 by 2030 and 41 by 2038.
Its sole original drug, Zymfentra (marketed as Remsima SC outside the U.S.), is available in the United States for treating autoimmune diseases. (192 words)
